Vitamin D3 for Life

Live Enlightened

Article

Vitamin D Supplementation and Clinical Iron Markers Across Populations: Full Study

Previous related pageVitamin D Regulation of Hepcidin, Ferroportin and Iron Mobilisation: Study SummaryNext related pageVitamin D Supplementation and Clinical Iron Markers Across Populations: Study Summary
Study at a glance

Do vitamin D supplements improve iron availability and red blood cell production?

This page compares vitamin D trials measuring iron availability and red blood cell production in different populations. Haemoglobin carries oxygen in red blood cells. Ferritin reflects iron stores but also changes with inflammation. Hepcidin helps control iron release from cells. A change in one of these measures does not guarantee that the others improve.

What did larger vitamin D trials find about iron measures?

In BEST-D, 305 adults aged 65 or older were randomly assigned to vitamin D3 or an inactive treatment for one year. Vitamin D levels rose, but the measured iron markers did not improve significantly. A review combining 14 trials with 1,385 participants likewise found no significant overall change in haemoglobin or ferritin. It found a modest improvement in transferrin saturation, a measure of how much of the blood’s iron-transport capacity is being used.

Were results different in people with kidney disease?

A 12-week trial completed by 85 people with chronic kidney disease found no overall improvement in hepcidin, iron measures or red blood cell production. Smaller groups within that trial showed different results depending on starting vitamin D levels. Dialysis trials also gave mixed results. One reported higher haemoglobin and lower need for a medicine that supports red blood cell production, without significant improvement in several iron markers.

Do vitamin D supplements reliably improve iron measures?

Vitamin D does not reliably improve iron measures across all populations. Lower hepcidin can sometimes be a response to worsening iron availability, rather than a sign of improvement. Starting vitamin D levels, kidney function, inflammation and iron stores affect interpretation. Findings from smaller groups need further confirmation and do not establish a personal vitamin D target or a universal treatment for anaemia.

Read the full article below ↓

A convincing molecular mechanism does not guarantee that vitamin D supplementation will improve haemoglobin, ferritin, serum iron or transferrin saturation in every population. That distinction is especially important in Vitamin D and Iron Metabolism. Short-duration studies show that vitamin D can suppress hepcidin, but larger and longer intervention studies produce a much more heterogeneous picture once age, kidney disease, baseline vitamin D status, inflammation and erythropoietic physiology are introduced. Clinical iron markers therefore provide a critical test of whether a mechanistic change in hepcidin translates into a measurable whole-body effect. For a shorter version, see Vitamin D Supplementation and Clinical Iron Markers Across Populations: Study Summary.

Clinical iron markers answer different questions

Haemoglobin reflects red-cell oxygen-carrying mass rather than iron availability alone. Ferritin reflects iron storage but is also influenced by inflammation. Serum iron is dynamic. Transferrin reflects iron-transport capacity, while transferrin saturation estimates the proportion of transferrin binding sites occupied by iron. Soluble transferrin receptor adds information about cellular iron demand and erythropoietic activity.

These markers therefore cannot be expected to move in lockstep. Vitamin D could theoretically lower hepcidin while ferritin remains unchanged, or improve iron availability without producing a large haemoglobin change if erythropoiesis is limited elsewhere. This is another example of the difference between measured status and downstream effect described in Vitamin D Status vs Vitamin D Effect.

BEST-D provides a strong long-duration null result

The BEST-D randomized trial provides important evidence because it studied community-dwelling adults aged 65 years or older over 12 months. A total of 305 participants were allocated to 4,000 IU vitamin D₃ daily, 2,000 IU daily, or placebo. Vitamin D supplementation substantially increased 25(OH)D, creating a clear biological exposure contrast.

Despite that increase, neither vitamin D dose significantly changed the measured markers of iron status or erythropoiesis. Hepcidin concentrations were essentially similar between vitamin-D and placebo groups. Soluble transferrin receptor, ferritin, serum iron, transferrin, transferrin saturation and the soluble-transferrin-receptor:ferritin index were also not significantly improved.

The proportions of participants meeting low-ferritin or low-transferrin-saturation criteria were likewise unaltered. This is a direct challenge to any universal proposition that increasing vitamin D status should lower hepcidin and improve iron availability in otherwise community-dwelling older adults.

The BEST-D result does not erase the hepcidin mechanism

Mechanistic evidence and BEST-D are not mutually exclusive. The earlier studies asked whether vitamin D could regulate hepcidin under particular experimental conditions. BEST-D asked whether sustained daily supplementation meaningfully altered iron markers in a specific older population over one year.

A biological pathway can be real without becoming rate-limiting in every population. If hepcidin is already appropriately regulated, if participants are not iron restricted, or if other physiological determinants dominate, further vitamin D exposure may produce little measurable change in iron outcomes.

This is consistent with Vitamin D Response. Baseline state can determine whether manipulating one input materially changes a downstream system.

Chronic kidney disease creates a more complicated physiological environment

Kidney disease is particularly relevant because renal function influences erythropoietin, inflammation, active vitamin D metabolism and hepcidin clearance. Anaemia in CKD can therefore emerge from several simultaneous mechanisms. The broader vitamin D consequences of renal physiology are developed in Vitamin D and Kidneys.

A randomized placebo-controlled study in stage G3-G4 CKD tested 8,000 IU cholecalciferol daily for 12 weeks. Eighty-five participants completed the trial. Supplementation markedly raised 25(OH)D, but there was no overall effect on hepcidin, erythropoiesis or iron-status markers across the complete cohort.

Subgroup results were more complicated. Participants with lower baseline 25(OH)D showed increases in haemoglobin and transferrin saturation compared with placebo. In participants starting with higher 25(OH)D, supplementation was associated with a different pattern, including lower haemoglobin and transferrin saturation within the treatment group alongside lower hepcidin relative to placebo.

Lower hepcidin can sometimes accompany worse iron status

The CKD subgroup finding is important because it prevents hepcidin from being interpreted in one direction. Hepcidin can fall because vitamin D signalling suppresses HAMP, but it can also fall when the body responds to worsening iron availability. A lower hepcidin concentration is therefore not automatically evidence of improved iron physiology.

The meaning depends on accompanying ferritin, transferrin saturation, haemoglobin, erythropoietic demand and disease state. This is why clinical markers need to be interpreted as a network rather than selecting the biomarker that best supports a preferred explanation.

Haemodialysis trials demonstrate further heterogeneity

A multicentre double-blind randomized trial in haemodialysis patients tested different cholecalciferol schedules over six months. The results did not reproduce a simple sustained hepcidin-lowering effect. Hepcidin was initially higher after vitamin D and later lower under some conditions, while erythropoietin resistance complicated interpretation.

Another randomized study in vitamin-D-deficient anaemic haemodialysis patients reported increased haemoglobin and lower erythropoietin requirements with monthly vitamin D supplementation, yet ferritin, serum iron and transferrin saturation did not differ significantly between groups. The clinical signal therefore appeared in erythropoiesis without uniform improvement across iron markers.

These divergent dialysis results reinforce the need for physiological stratification. Renal anaemia is not merely iron deficiency plus low vitamin D. It includes impaired erythropoietin production or responsiveness, altered hepcidin clearance, inflammation and treatment effects.

Meta-analysis also separates haemoglobin from iron availability

A systematic review and meta-analysis of 14 randomized trials involving 1,385 participants examined vitamin D supplementation and haemoglobin as its primary outcome. Across the included trials, vitamin D supplementation did not significantly change haemoglobin. Ferritin also showed no significant overall effect.

Transferrin saturation showed a modest positive pooled effect, while broader iron-status measures showed some improvement. This pattern again demonstrates that different iron endpoints can move differently. Increased circulating availability does not necessarily create a detectable haemoglobin response over the same timescale.

Baseline vitamin D status may identify some responsive contexts

Several intervention datasets suggest that baseline vitamin D status can modify response. That possibility is biologically plausible because adding vitamin D where signalling is already relatively replete may have little effect, while correcting substantial insufficiency could affect a pathway that was previously constrained.

However, subgroup observations are weaker than consistently replicated primary trial outcomes. They should therefore generate a stratified physiological hypothesis rather than a universal clinical threshold. The same caution applies to Functional Vitamin D Status: response variation does not establish a personalised treatment target by itself.

Why ferritin is particularly difficult to interpret

Ferritin sits at the intersection of iron stores and inflammation. In inflammatory disease, ferritin can be raised independently of readily available iron. During improvement in inflammation, ferritin may fall even when iron handling improves. In iron depletion, ferritin can fall because stores are genuinely low.

A vitamin D intervention can therefore create apparently contradictory ferritin results depending on which physiology dominates. This is why the inflammatory context from Vitamin D and Inflammatory Signalling must remain visible when interpreting iron trials.

What the clinical evidence establishes

The clinical evidence does not support a uniform vitamin-D-to-iron outcome. Vitamin D can suppress hepcidin under some experimental and human conditions, but sustained supplementation does not reliably improve hepcidin, ferritin, haemoglobin, serum iron or transferrin saturation across populations.

Population, baseline vitamin D status, kidney function, inflammation, iron stores and erythropoietic physiology all modify interpretation. The scientific value of the evidence lies partly in this heterogeneity: it shows where a plausible mechanism stops being a universal prediction.

The integrated interpretation is developed in Vitamin D, Hepcidin, Iron Availability and Anaemia: Evidence Synthesis.

Scientific sources

Effect of supplementation with vitamin D on biochemical markers of iron status and erythropoiesis in older people: BEST-D trial. PMID: 40452069.

The effect of high-dose vitamin D supplementation on hepcidin-25 and erythropoiesis in patients with chronic kidney disease. PMID: 36698076.

The effect of vitamin D supplementation on hemoglobin concentration: a systematic review and meta-analysis. PMID: 32013954.

Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial. PMID: 32968158.

Effect of vitamin D supplementation on management of anemia in hemodialysis patients with vitamin D deficiency: A double-blind, randomized, controlled trial. PMID: 37853507.

Related reading

Original sources

Source

Effect of supplementation with vitamin D on biochemical markers of iron status and erythropoiesis in older people: BEST-D trial

The BEST-D trial, designed to establish the optimum dose of vitamin D3 for future trials, had 305 participants, aged 65 years or older, randomly allocated to 4000 IU vitamin D3 (n 102), 2000 IU vitamin D3 (n 102) or matching placebo (n 101).

Publication details

Effect of supplementation with vitamin D on biochemical markers of iron status and erythropoiesis in older people: BEST-D trial. PMID: 40452069.

Read more →
Source

Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial

In this multicentre double-blind randomized clinical trial, we investigated the effects of oral cholecalciferol supplementation on serum hepcidin and parameters related to anaemia and CKD-MBD among haemodialysis patients.

Publication details

Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial. PMID: 32968158.

Read more →
Source

Effect of vitamin D supplementation on management of anemia in hemodialysis patients with vitamin D deficiency: A double-blind, randomized, controlled trial

Effect of vitamin D supplementation on management of anemia in hemodialysis patients with vitamin D deficiency: A double-blind, randomized, controlled trial.

Publication details

Effect of vitamin D supplementation on management of anemia in hemodialysis patients with vitamin D deficiency: A double-blind, randomized, controlled trial. PMID: 37853507.

Read more →